MCID: LRY013
MIFTS: 16

Laryngeal Neuroendocrine Tumor

Categories: Endocrine diseases, Rare diseases, Cancer diseases, Respiratory diseases, Neuronal diseases, Oral diseases

Aliases & Classifications for Laryngeal Neuroendocrine Tumor

MalaCards integrated aliases for Laryngeal Neuroendocrine Tumor:

Name: Laryngeal Neuroendocrine Tumor 12 56
Neuroendocrine Neoplasm of Larynx 69
Neuroendocrine Tumor of Larynx 12

Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:5457
NCIt 47 C6023
SNOMED-CT 64 707625001
Orphanet 56 ORPHA100083
UMLS 69 C1334374

Summaries for Laryngeal Neuroendocrine Tumor

MalaCards based summary : Laryngeal Neuroendocrine Tumor, also known as neuroendocrine neoplasm of larynx, is related to neuroendocrine tumor. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and liver.

Related Diseases for Laryngeal Neuroendocrine Tumor

Diseases related to Laryngeal Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 9.7

Symptoms & Phenotypes for Laryngeal Neuroendocrine Tumor

Drugs & Therapeutics for Laryngeal Neuroendocrine Tumor

Drugs for Laryngeal Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Liver Extracts Phase 3,Phase 2,Phase 1
4 Adjuvants, Anesthesia Phase 3
5 Analgesics Phase 3
6 Analgesics, Opioid Phase 3
7 Anesthetics Phase 3
8 Anesthetics, General Phase 3
9 Anesthetics, Intravenous Phase 3
10 Central Nervous System Depressants Phase 3
11 Narcotics Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Cola Nutraceutical Phase 3,Phase 2,Phase 1
14
Indinavir Approved Phase 2 150378-17-9 5362440
15
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
16
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
17
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
18 Anti-HIV Agents Phase 2
19 Anti-Infective Agents Phase 2,Phase 1
20 Anti-Retroviral Agents Phase 2
21 Antiviral Agents Phase 2,Phase 1
22 Cytochrome P-450 CYP3A Inhibitors Phase 2
23 Cytochrome P-450 Enzyme Inhibitors Phase 2
24 HIV Protease Inhibitors Phase 2
25
protease inhibitors Phase 2
26 Vaccines Phase 2
27 Antimitotic Agents Phase 2,Phase 1
28
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
29
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
30
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
31
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
32
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
33
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
34
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
35
Gemcitabine Approved Phase 1 95058-81-4 60750
36
Lenograstim Approved Phase 1 135968-09-1
37
7-hydroxystaurosporine Experimental Phase 1 112953-11-4 72271
38
Camptothecin Experimental Phase 1 7689-03-4
39 Staurosporine Experimental Phase 1 62996-74-1
40
Entinostat Investigational Phase 1 209783-80-2
41 Adjuvants, Immunologic Phase 1
42 Albumin-Bound Paclitaxel Phase 1
43 Angiogenesis Inhibitors Phase 1
44 Angiogenesis Modulating Agents Phase 1
45 Antineoplastic Agents, Phytogenic Phase 1
46 Interleukin-12 Phase 1
47 Protein Kinase Inhibitors Phase 1
48 topoisomerase I inhibitors Phase 1
49 Topoisomerase Inhibitors Phase 1
50 Antibodies Phase 1

Interventional clinical trials:

(show all 17)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
3 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
4 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
5 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
6 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
7 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
8 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
9 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
10 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
11 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
12 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
13 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
14 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
15 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 gefitinib
16 Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 Completed NCT01015963
17 Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers Recruiting NCT00900419

Search NIH Clinical Center for Laryngeal Neuroendocrine Tumor

Genetic Tests for Laryngeal Neuroendocrine Tumor

Anatomical Context for Laryngeal Neuroendocrine Tumor

MalaCards organs/tissues related to Laryngeal Neuroendocrine Tumor:

39
Lung, Breast, Liver, Brain

Publications for Laryngeal Neuroendocrine Tumor

Variations for Laryngeal Neuroendocrine Tumor

Expression for Laryngeal Neuroendocrine Tumor

Search GEO for disease gene expression data for Laryngeal Neuroendocrine Tumor.

Pathways for Laryngeal Neuroendocrine Tumor

GO Terms for Laryngeal Neuroendocrine Tumor

Sources for Laryngeal Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....